SWK Holdings Corp (SWKH)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Finance receivables segment | - | 110 | - | - |
| Pharmaceutical development and other segment | - | 47 | - | - |
| Total revenues | 10,052 | 11,832 | 10,418 | 11,541 |
| Pharmaceutical manufacturing, research and development expense | 645 | 758 | 585 | 520 |
| Provision (benefit) for credit losses | 761 | -1,465 | 1,385 | 4,074 |
| Interest expense | 1,155 | 1,130 | 1,139 | - |
| Loss on impairment of intangibles assets | - | - | - | - |
| General and administrative expense | 2,843 | 3,277 | 2,993 | 2,923 |
| Depreciation and amortization expense | 19 | 19 | 234 | - |
| Change in fair value of acquisition-related contingent consideration | - | - | - | - |
| Income from operations | 4,629 | 8,113 | 4,082 | - |
| Net gain (loss) on marketable investments | 37 | -105 | - | - |
| Realized gain on early payment of finance receivable | - | 1,729 | - | - |
| Loss on sale of assets | - | -82 | - | 3 |
| Realized and unrealized foreign currency transaction gains (losses) | -451 | 313 | 251 | - |
| Gain (loss) on revaluation of finance receivables | - | -3,727 | - | 2,495 |
| Net gain on exercise and cancellation of warrants | - | - | - | - |
| Unrealized net gain (loss) on warrants | 347 | -424 | 47 | 226 |
| Unrealized net (loss) gain on marketable investments | - | - | -6 | - |
| Income before income tax expense | 4,562 | 5,817 | 4,374 | - |
| Income tax expense | 1,026 | 1,278 | 906 | 1,035 |
| Net income | 3,536 | 4,539 | 3,468 | 4,395 |
| Realized and unrealized foreign currency transaction gains | - | - | - | 437 |
| Interest expense, operating and nonoperating | - | - | - | 1,119 |
| Loss on impairment intangible assets | - | - | - | 5,771 |
| Depreciation and amortization expense | - | - | - | 421 |
| Change in fair value of acquisition-related contingent consideration | - | - | - | -4,900 |
| Costs and expenses | - | - | - | -1,613 |
| Net realized gain on exercise of warrants | - | - | - | 656 |
| Income (loss) from continuing operations before equity method investments, income taxes, noncontrolling interest | - | - | - | 5,430 |
| Net income (loss) | - | - | - | 4,395 |
| Basic (in dollars per share) | 0.29 | 0.37 | 0.28 | 0.35 |
| Basic (in shares) | 12,208,000 | 12,229,000 | 12,318,000 | 12,457,000 |
| Diluted (in dollars per share) | 0.29 | 0.37 | 0.28 | 0.35 |
| Diluted (in shares) | 12,208,000 | 12,240,000 | 12,408,000 | 12,528,000 |